Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma - Full Text View

Purpose

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a patient's white blood cells with interleukin-2 may stimulate them to kill tumor cells.

PURPOSE: This phase II trial is studying how well giving chemotherapy together with biological therapy works in treating patients with metastatic melanoma that has not responded to previous therapy.

Condition	Intervention	Phase
Melanoma (Skin)	Drug: MART-1 antigen Drug: aldesleukin Drug: cyclophosphamide Drug: filgrastim Drug: fludarabine phosphate Drug: gp100 antigen Drug: incomplete Freund's adjuvant Drug: therapeutic autologous lymphocytes Drug: therapeutic tumor infiltrating lymphocytes Procedure: chemotherapy Procedure: colony-stimulating factor therapy Procedure: gene therapy Procedure: interleukin therapy Procedure: non-specific immune-modulator therapy Procedure: peripheral blood lymphocyte therapy Procedure: tumor infiltrating lymphocyte therapy	Phase II

MedlinePlus related topics:

Melanoma Skin Cancer

ChemIDplus related topics:

Granulocyte-macrophage colony-stimulating factor Sargramostim Cyclophosphamide Filgrastim Fludarabine Fludarabine monophosphate Aldesleukin Freund's adjuvant Montanide ISA 51

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Open Label

Official Title:	Treatment of Patients With Metastatic Melanoma Using Cloned Lymphocytes Following the Administration of a Nonmyeloablative But Lymphocyte Depleting Regimen

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

Clinical tumor regression [ Designated as safety issue: No ]

Secondary Outcome Measures:

Safety [ Designated as safety issue: Yes ]
Survival [ Designated as safety issue: No ]
Long-term immune status [ Designated as safety issue: No ]
Clinical response [ Designated as safety issue: No ]
Impact of administering infused cells without filgrastim (G-CSF) [ Designated as safety issue: No ]

Estimated Enrollment:	220
Study Start Date:	September 1999
Estimated Primary Completion Date:	September 2005 (Final data collection date for primary outcome measure)

Show Detailed Description

Eligibility

Ages Eligible for Study:	16 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Diagnosis of metastatic melanoma that is refractory to therapy
Evaluable disease

PATIENT CHARACTERISTICS:

Age

16 and over

Performance status

ECOG 0-1

Life expectancy

More than 3 months

Hematopoietic

Absolute neutrophil count greater than 1,000/mm^3
Platelet count greater than 100,000/mm^3
Hemoglobin greater than 8.0 g/dL
No coagulation disorder

Hepatic

Bilirubin no greater than 1.6 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome)
AST/ALT less than 2 times upper limit of normal
Hepatitis B surface antigen negative

Renal

Creatinine no greater than 1.6 mg/dL

Cardiovascular

No major medical illness of the cardiovascular system

Pulmonary

No major medical illness of the respiratory system

Other

No major medical illness of the immune system
No active systemic infection
HIV negative
Not pregnant
Negative pregnancy test
Fertile patients must use effective contraception during and for 4 months after study participation
Must sign a durable power of attorney

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

Not specified

Endocrine therapy

No concurrent steroid therapy

Radiotherapy

Not specified

Surgery

Not specified

Other

More than 4 weeks since any prior therapy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00019942

Locations


United States, Maryland
	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office	Recruiting
	Bethesda, Maryland, United States, 20892-1182
	Contact: Patient Recruitment 866-820-4505

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators


Study Chair:	Steven A. Rosenberg, MD, PhD	NCI - Surgery Branch

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

Featured trial article This link exits the ClinicalTrials.gov site

Publications of Results:

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002 Oct 25;298(5594):850-4. Epub 2002 Sep 19.

Study ID Numbers:	CDR0000067331, NCI-99-C-0158, NCI-T99-0078
First Received:	July 11, 2001
Last Updated:	April 29, 2008
ClinicalTrials.gov Identifier:	NCT00019942
Health Authority:	Unspecified

Keywords provided by National Cancer Institute (NCI):

stage IV melanoma

recurrent melanoma

Study placed in the following topic categories:

Cyclophosphamide

Fludarabine monophosphate

Recurrence

Melanoma

Neuroendocrine Tumors

Neuroectodermal Tumors

Aldesleukin

Neoplasms, Germ Cell and Embryonal

Nevus, Pigmented

Neuroepithelioma

Freund's Adjuvant

Nevus

Fludarabine

Additional relevant MeSH terms:

Antimetabolites

Anti-Infective Agents

Anti-HIV Agents

Antimetabolites, Antineoplastic

Neoplasms by Histologic Type

Immunologic Factors

Molecular Mechanisms of Pharmacological Action

Antineoplastic Agents

Neoplasms, Nerve Tissue

Physiological Effects of Drugs

Adjuvants, Immunologic

Antiviral Agents

Immunosuppressive Agents

Pharmacologic Actions

Neoplasms

Anti-Retroviral Agents

Therapeutic Uses

Myeloablative Agonists

Nevi and Melanomas

Antineoplastic Agents, Alkylating

ClinicalTrials.gov processed this record on May 12, 2008

Sponsored by:	National Cancer Institute (NCI)
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00019942